ACF reduced CML development and decreased the number of long-term LSCs in vivo. CML mice were treated daily for 10 days with ACF or placebo and euthanized after 1 additional day. (A) Number of BM viable cells. (B) Relative number of GFP⁺ (leukemic) or GFP⁻ (nonleukemic) cells in BM; data are expressed as fraction of the value obtained for placebo. (C) Apoptotic rate of GFP⁺ or GFP⁻ BM cells. (D) Percentage (left) and relative number (right) of GFP⁺ or GFP⁻/LT-LSK cells in BM; data are expressed as fraction of the value obtained for placebo. (A-D) Values represent mean ± S.D. of data from 8 mice per experimental variant. ACF- vs PBS-treated mice: *P ≤ .05, **P ≤ .01, ***P ≤ .001; ACF-treated mice, GFP⁻ vs GFP⁺ cells: §P ≤ .05, §§P ≤ .01.